High-Purity Pharmaceutical Intermediate for Tegoprazan Synthesis
Essential precursor for advanced P-CAB therapies, ensuring quality and efficacy in acid-related disorder treatments.
Get a Quote & SampleProduct Core Value
![4-Hydroxy-N,N,2-Trimethyl-1-Tosyl-1H-Benzo[d]Imidazole-6-Carboxamide](https://www.nbinno.com/webimg/gemini_6880e037b60a5_1753276471.png)
4-Hydroxy-N,N,2-Trimethyl-1-Tosyl-1H-Benzo[d]Imidazole-6-Carboxamide
This pharmaceutical intermediate is a critical component in the synthesis of Tegoprazan, a novel potassium-competitive acid blocker (P-CAB) designed for the effective treatment of various acid-related gastrointestinal conditions, including GERD and gastric ulcers.
- Key intermediate for manufacturing Tegoprazan, a novel Potassium-Competitive Acid Blocker (P-CAB), facilitating efficient acid suppression.
- Facilitates the development of next-generation acid suppression therapies, offering improved patient outcomes.
- Manufactured under stringent quality control, adhering to GMP, ISO 9001, and FDA standards for assured product integrity.
- Supports custom synthesis needs, providing tailored solutions for specific pharmaceutical research and development requirements.
Advantages of Utilizing This Intermediate
Enhanced Therapeutic Efficacy
Utilizing this high-purity Tegoprazan intermediate is key to the manufacturing process development for Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB), directly contributing to more effective treatment of acid-related conditions.
Guaranteed Quality Standards
With certifications like GMP, ISO 9001, and FDA, this intermediate ensures that the final pharmaceutical product meets rigorous international quality benchmarks, vital for patient safety and therapeutic success.
Scalable Production Capabilities
The reliable supply of this intermediate supports the scalable production of Tegoprazan, ensuring that demand for advanced gastrointestinal drug intermediates can be met consistently.
Key Applications
Pharmaceutical Synthesis
Serves as a fundamental building block for the synthesis of Tegoprazan, a key P-CAB API, enabling the production of innovative treatments for acid-related disorders.
Drug Development
Supports the ongoing research and development of new gastrointestinal medications, offering a reliable precursor for novel P-CAB formulations.
Acid-Related Disorder Treatment
Crucial for manufacturing drugs that target GERD, erosive esophagitis, and gastric ulcers, improving patient quality of life through effective acid suppression.
Chemical Research
Valuable for chemical research focusing on the development of advanced pharmaceutical intermediates and the synthesis of complex organic molecules.